- Current report filing (8-K)
July 11 2011 - 9:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): July 11, 2011
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
No. 14 East Hushan Road,
Tai'an City, Shandong,
271000
People's Republic of China
(Address of Principal
Executive Offices)
86-538 -620-2306
Registrant's telephone number,
including area code
____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01. Other
Events
On July 11, 2011, China Biologic Products, Inc. issued a press
release relating to a Plan for Guizhou Provincial Blood Collection
Institutional Setting (2011-2014) issued by the Guizhou Provincial Health
Bureau and a press release relating to its opening of a plasma collection
station in Shandong province. A copy of these press releases is attached hereto
as Exhibit 99.1 and Exhibit 99.2 and is incorporated herein by reference.
Item 9.01 Financial Statements
and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: July 11, 2011
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
By:
/s/ Chao Ming Zhao
|
|
Chao Ming Zhao
|
|
Chief Executive Officer
|
EXHIBIT INDEX
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024